UNSPSC 51283941: Sulfacetamide sodium

This classification denotes a sulfonamide anti-infective agent with the molecular formula C8H9N2O3S.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4NRT660KJQ, chemically known as sulfanilamide, n(sup 1)-acetyl- but more generally known as sulfacetamide sodium, which bears US NIH Compound Identifier 5320. European Medicines Agency schedules Sulfacetamide sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04620MIG.

Most nations, for tariff and trade purposes, schedule sulfacetamide sodium under HS 29350090 and SITC 51580. As of Q4 2014, SULFACETAMIDE SODIUM remains US FDA's Preferred Term for this commodity. Sulfacetamide sodium bears US NLM identifiers UMLS ID C0282356 and NCI Concept Code C29467. SMILES: CC(=O)[N-]S(=O)(=O)C1CCC(CC1)N.O.[NA+].

UNSPSC 51283941 Sulfacetamide sodium is a Commodity code that nominally describes a specific pharmaceutical product, but recent state and local solicitations tagged under this code show significant scope misalignment. The recent opportunities target naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products — none of which are sulfacetamide sodium preparations. The code shows little relevant recent activity aligned with its stated commodity scope; the opportunities appear to reflect broader pharmaceutical, medical supply, and emergency response procurement rather than the specific ophthalmic or dermatological sulfacetamide sodium product the code nominally covers.

Recent solicitations originate from diverse issuing bodies spanning county health departments, state health and human services agencies, municipalities, and cooperative purchasing alliances. Seminole County, Florida issued an IFB in mid-2026 for naloxone and drug deactivation systems with quarterly deliveries; the City of Tampa's Purchasing Department issued an IFB for medical and first aid supplies designated as a sheltered market opportunity for certified Small Local Business Enterprises with an estimated contract value of $700,000; the Texas Health and Human Services Commission issued an RFI in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in early 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, to be distributed across state and local facilities including Oregon. Geographic activity spans Florida, Texas, Minnesota, and Oregon, with the cooperative purchasing vehicle extending across multiple jurisdictions. The code's tagging does not reflect sulfacetamide sodium procurement activity and may indicate a data-classification issue rather than legitimate market opportunity under this commodity code.